<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01519297</url>
  </required_header>
  <id_info>
    <org_study_id>PP PE 2012</org_study_id>
    <nct_id>NCT01519297</nct_id>
  </id_info>
  <brief_title>Preeclampsia: A Marker for Future Cardiovascular Risk in Women</brief_title>
  <official_title>Preeclampsia: A Marker for Future Cardiovascular Risk in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare blood vessel and hormone differences between women who have a history&#xD;
      of a pregnancy complicated by preeclampsia or high blood pressure, and women who have a&#xD;
      history of uncomplicated pregnancy in the last 10 years. The investigators hypothesize that&#xD;
      postpartum women with history of preeclampsia will have altered blood vessel function and&#xD;
      abnormal hormone levels compared with postpartum women with history of uncomplicated&#xD;
      pregnancy.&#xD;
&#xD;
      This study will take place over the course of 2 weeks. Each subject will be assessed on a&#xD;
      fixed low-salt diet and a fixed high-salt diet. Subjects will have 2 non-invasive blood&#xD;
      vessel imaging tests and fasting blood draws.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Pending funding&#xD;
  </why_stopped>
  <start_date type="Actual">May 2012</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vascular function</measure>
    <time_frame>60 minutes</time_frame>
    <description>Assess vascular function after administration of an angiotensin receptor blocker.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hormonal measurements</measure>
    <time_frame>60 minutes</time_frame>
    <description>Assess hormone levels pertaining to the renin-angiotensin system after administration of irbesartan.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Preeclampsia</condition>
  <condition>Pregnancy Induced Hypertension</condition>
  <arm_group>
    <arm_group_label>Single arm intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Irbesartan 150 mg orally for one dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irbesartan</intervention_name>
    <description>150mg orally for one dose</description>
    <arm_group_label>Single arm intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy female premenopausal volunteers, with regular menstrual cycles (at least 8&#xD;
             cycles per year)&#xD;
&#xD;
          2. Age 21 to 50 years&#xD;
&#xD;
          3. Systolic blood pressure &lt;140 and &gt;90 mmHg and diastolic blood pressure &lt;90 and &gt;60&#xD;
             mmHg at the screening visit&#xD;
&#xD;
          4. Body mass index &lt; 35 kg/m2&#xD;
&#xD;
          5. History of normotensive pregnancy or history of preeclamptic or hypertensive pregnancy&#xD;
             within the last 10 years&#xD;
&#xD;
          6. No clinically significant abnormalities on screening tests (complete blood count,&#xD;
             serum electrolytes, liver enzymes, thyroid stimulating hormone, urinalysis, and&#xD;
             electrocardiogram)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current pregnancy&#xD;
&#xD;
          2. Lactation&#xD;
&#xD;
          3. Elevated blood pressure (systolic blood pressure &gt; 140 mmHg or diastolic blood&#xD;
             pressure &gt; 90 mmHg)&#xD;
&#xD;
          4. Current diagnosis of hypertension&#xD;
&#xD;
          5. Current diagnosis of diabetes mellitus&#xD;
&#xD;
          6. Personal history of coronary disease, stroke and kidney disease&#xD;
&#xD;
          7. Use of prescription medications (with the exception of stable thyroid hormone&#xD;
             replacement dose) within 2 weeks of study&#xD;
&#xD;
          8. Use of oral contraceptives or other hormone therapy within 3 months of study;&#xD;
&#xD;
          9. Renal impairment (estimated GFR&lt;60)&#xD;
&#xD;
         10. Active liver disease (AST, ALT, alkaline phosphatase &gt; 1.5 times normal);&#xD;
&#xD;
         11. Current smoking, defined as smoking within the 6 months before the screening visit&#xD;
&#xD;
         12. Current or past recreational drug use&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen W Seely, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 23, 2012</study_first_submitted>
  <study_first_submitted_qc>January 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2012</study_first_posted>
  <last_update_submitted>January 15, 2019</last_update_submitted>
  <last_update_submitted_qc>January 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Ellen W. Seely</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>Preeclampsia</keyword>
  <keyword>Pregnancy Induced Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pre-Eclampsia</mesh_term>
    <mesh_term>Hypertension, Pregnancy-Induced</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irbesartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

